💬In plain words
What the trial is, and whether it could suit you
In the context of the accelerating aging population and the continuous decline in birth rates nationwide, delaying reproductive aging in women and protecting the fertility of women of childbearing age have become urgent issues and key demands that need to be addressed in the field of maternal and child health in China. The ovaries have reproductive and hormone secretion functions and are crucial throughout the female reproductive lifecycle. Women of childbearing age in China face a serious problem of diminished ovarian reserve (DOR), which can lead to infertility, failed in vitro fertilization (IVF) treatments, miscarriage, and other adverse pregnancy outcomes, severely affecting the safety of women and their offspring. For DOR patients who desire to conceive, failure to intervene and treat promptly can result in irreversible losses and impose a significant psychological burden on them.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Definition of DOR: Currently, there is no internationally unified standard for DOR. According to the latest POSEIDON criteria for diminished ovarian reserve (DOR), serum AMH \<1.20 ng/mL or bilateral antral follicle count (AFC) \<5 is classified as DOR.
In this study, the participants are primarily DOR patients, with the following inclusion criteria:
* Infertile women undergoing their 1st or 2nd IVF treatment
* Diagnosed with DOR: POSEIDON criteria (AMH \<1.2 ng/mL or bilateral AFC \<5) BMI between 18.5-28.0 kg/m²
* Signed informed consent
Exclusion Criteria：Participants meeting any of the following criteria will be excluded from the trial:
* PGT (preimplantation genetic testing) candidates
* DOR caused by ovarian surgery, cancer radiotherapy/chemotherapy
* Other ovulation disorders (e.g., PCOS, Cushing's syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia) or endometriosis (chocolate cysts)
* Severe thyroid disorders: Hyperthyroidism, Graves' disease, Hashimoto's thyroiditis
* Acute/chronic renal insufficiency, hemodialysis, or history of severe kidney impairment
* Infectious diseases: HIV, active hepatitis, metabolic acidosis, tuberculosis, etc.
* Severe autoimmune diseases (e.g., rheumatoid arthritis, lupus, Crohn's disease)
* Cardiovascular events within the past 3 months: Coronary artery disease/myocardial infarction/clinically significant congestive heart failure；Stroke/transient ischemic attack (TIA)；Deep vein thrombosis/pulmonary embolism；Poorly controlled hypertension (SBP ≥160 mmHg or DBP ≥90 mmHg)；Diagnosed diabetes mellitus；Coronary intervention (PCI) or coronary artery bypass grafting (CABG)；
* Neurological disorders (e.g., dementia,Alzheimer's, Parkinson's) or use of related medications
* Psychiatric disorders or use of antiepileptic/antidepressant drugs
* History of cancer or radiotherapy/chemotherapy
* Allergy to vitamin C
* Current high-dose vitamin C supplementation (\>500 mg/day)
* Unwillingness to take the study-provided supplements
* Alcohol abuse, smoking, or drug addiction
* Participation in other clinical trials within the past month
HealthTeky